Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures usually occur early after infusion. The purpose of our study was to identify factors that may predict failure, particularly early...

Full description

Bibliographic Details

Published in:	Blood advances Vol. 4; no. 22; pp. 5607 - 5615
Main Authors:	Vercellino, Laetitia, Di Blasi, Roberta, Kanoun, Salim, Tessoulin, Benoit, Rossi, Cedric, D'Aveni-Piney, Maud, Obéric, Lucie, Bodet-Milin, Caroline, Bories, Pierre, Olivier, Pierre, Lafon, Ingrid, Berriolo-Riedinger, Alina, Galli, Eugenio, Bernard, Sophie, Rubio, Marie-Thérèse, Bossard, Celine, Meignin, Veronique, Merlet, Pascal, Feugier, Pierre, Le Gouill, Steven, Ysebaert, Loic, Casasnovas, Olivier, Meignan, Michel, Chevret, Sylvie, Thieblemont, Catherine
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 24.11.2020 The American Society of Hematology American Society of Hematology
Subjects:	Cancer Hematology Human health and pathology Humans Immunotherapy, Adoptive Life Sciences Lymphoid Neoplasia Lymphoma, Large B-Cell, Diffuse - diagnosis Lymphoma, Large B-Cell, Diffuse - therapy Progression-Free Survival Retrospective Studies Tumor Burden
ISSN:	2473-9529, 2473-9537, 2473-9537
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!